OC-0202: A randomised controlled trial of intensity modulated radiotherapy (IMRT) for early breast cancer: results at 5 years  by Coles, C.E. et al.
2nd ESTRO Forum 2013  S79 
	
 SYMPOSIUM: BREAST  
  
SP-0200   
Optimisation of locoregional control: Modified fractionation and/or 
radiation techniques eg Z11 high tangents etc 
I. Kunkler1 
1Edinburgh Cancer Centre University of Edinburgh, Radiation 
Oncology, Edinburgh, United Kingdom  
 
Hypofractionated postoperative radiotherapy [RT] (2) is now  the 
standard of care for virtually all patients with  early breast cancer 
requiring adjuvant RT. This has been practice changing worldwide 
except in the USA where there is more caution on the generalisability 
of  level 1 evidence (3). Current research focuses on identifying the 
limits of hypofractionation. The UK FAST trial compared two dose 
levels (5.7 Gy and 6.0Gy) of a 5 fraction regime giving one 
fraction/week with a control schedule of 50 Gy in 25 fractions (4). 
Moderate/marked adverse effects were greater with 30 Gy compared 
to 50 Gy but similar with 28.5 Gy. The FAST FORWARD trial (5) is 
comparing two 5 fractions regimens (27 Gy [5.4Gy/fr] and 26 Gy [5.2 
Gy/fr) over a week with a standard 3 week schedule. Access to 
intensity modulated RT (IMRT) has permitted delivery of a 
simultaneous integrated breast boost to the site of excision and is the 
subject  of ongoing trials (6,7) 
There is  controversy over the role of axillary nodal RT in patients 
with a positive sentinel node biopsy. (SLNB). Traditionally axillary  
lymph node dissection (ALND) has been the standard treatment for 
SNLB patients with early breast cancer, even for a single 
micrometastasis.  
The role of ALDN in early breast cancer was examined in the ACOSOG 
Z11 trial (8). SNLB positive patients after breast conserving surgery 
(BCS) were randomised to ALDN or no further RT if they were node 
positive. Unfortunately the trial did not reach its target accrual for 
which it was powered. There was no difference in regional recurrence 
or DFS. Some have concluded that ALDN may not be necessary, even 
for a SLN macrometastasis. Others have argued that the lack of QA of 
axillary RT in the trial may have obscured any tendency to place the 
upper border of the tangent fields higher in the  SNLB alone arm of 
the trial (‘high tangents’)  to cover level 1-11 axillary nodes. However 
more recent studies suggest that ‘high tangents’ are unlikely to 
deliver a cancericidal dose, even to the lower axillary nodes.  
Regional nodal irradiation (RNI) is an alternative to ALND for  SNLB 
positive patients. Its role is being investigated in the AMAROS trial (9)  
in women with any number or size of positive SLNs after BCS or 
mastectomy. Patients are randomised to ALDN or axillary RT. Accrual 
is complete and results are awaited. The NCIC-CTG MA20 trial 
evaluated RNI in high risk pN0 or pN1 patients in addition to whole 
breast RT after BCS and ALND (10). There was a 1.6% gain in OS from 
the addition of RNI and a 5.7% benefit in DFS. The downside was a 
1.1% increase in pneumonitis and 3.2% increase in lymphoedema. 
At present practice varies in the selection of patients for axillary RT 
after a positive SLNB. Regional recurrence rates after ALND or RNI 
may be low at 1-2%. RNI carries a lower risk of lymphoedema than 
ALDN but a higher risk of impaired shoulder function.  The POSNOC 
trial plans to examine the role of RNI in low volume axillary disease. 
The hypothesis of the trial is that clinically and ultrasound axillary 
node negative patients with 1-2 involved SLN macrometastases would 
have non inferior clinical outcomes whether randomised to axillary RT 
orto ALND (11). The primary endpoint of the trial is axillary 
recurrence at 5 years. The trial will be subject to an RT quality 
assurance programme. 
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Chemotherapy and radiotherapy associations have improved the 
prognosis of  most cancers. Their role for breast cancers is evolving. In 
the adjuvant setting, three phase III randomised trials, and several 
retrospective studies, suggested the benefit of chemoradiotherapy, 
especially for locally advanced breast cancers, at the cost of 
increased acute and late toxicities and poorer cosmetic effects. The 
benefit of new regimens of chemoradiotherapy need to be evaluated. 
In the neoadjuvant setting, breast chemoradiotherapy should permit 
to increase the breast conservation rate, while its administration in 
rescue after failure of neoadjuvant chemotherapy could enable 
surgical procedure. A better knowledge of the cancer biology would 
be worth incorporating into therapeutic strategies in order to better 
determine the need for chemoradiotherapy and its modalities for 
breast cancers. 
 
OC-0202   
A randomised controlled trial of intensity modulated radiotherapy 
(IMRT) for early breast cancer: results at 5 years  
C.E. Coles1, M. Mukesh1, G.C. Barnett1, J.S. Wilkinson1, A.M. Moody1, 
C.B. Wilson1, L. Dorling2, W. Qian3, N. Twyman1, N.G. Burnet1 
1Addenbrooke's Hospital, Oncology Centre, Cambridge, United 
Kingdom  
2Strangeways Research Laboratory, Genectics, Cambridge, United 
Kingdom  
3Addenbrooke's Hospital, Cambridge Trial Unit, Cambridge, United 
Kingdom  
 
Purpose/Objective: Intensity modulated radiotherapy (IMRT) im-
proves dose homogeneity across the breast. However, there is little 
randomised controlled trial data to confirm that improved homogenei-
ty with IMRT decreases late breast tissue toxicity. The Cambridge 
Breast IMRT trial investigated this hypothesis and the 5 year results 
are reported. 
Materials and Methods: The standard tangential plans of 1145 unse-
lected trial patients were analysed. 815 (71%) patients had inhomoge-
neous plans (≥ 2 cm3 receiving 107% of the prescribed dose: 40 Gy in 
15 fractions over 3 weeks) and were randomised to standard radiothe-
rapy (RT) or re-planned with forward planned IMRT. Late breast tissue 
toxicities were assessed at 5 years using validated methods: photo-
graphic assessment (overall cosmesis and breast shrinkage compared 
to baseline pre-RT photographs) and clinical assessment (telengiecta-
sia, induration, oedema and pigmentation). The difference in these 
endpoints between randomised groups was analysed using polycho-
tomous logistic regression. Data from all trial patients were also used 
to assess the effect of baseline (pre-RT) surgical cosmesis on these 
late toxicity endpoints. 
Results: The late normal tissue toxicity outcome at 5 years was 
available for 654/1145 (57%) and 465/815 (57%) for all patients and 
randomised patients respectively. On univariate analysis, fewer 
patients in the IMRT group developed skin telengiectasia (OR 0.58, 
95% CI 0.36-0.92; p=0.02) and sub-optimal overall cosmesis (OR 0.67, 
95% CI 0.48-0.96; p=0.027) compared with patients receiving standard 
RT. No significant difference was seen for photographically assessed 
breast shrinkage, breast oedema, tumour bed induration and pigmen-
tation between the two groups. The benefit of IMRT over standard RT 
was maintained on multivariate analysis for both skin telengiectasia 
(p=0.031) and overall cosmesis (p=0.038). Patients with poor baseline 
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surgical cosmesis were more likely to develop photographically as-
sessed breast shrinkage (OR 1.54, 95% CI 1.21-1.96; p<0.001), tumour 
bed induration (OR 1.80, 95% CI 1.43-2.26; p<0.001) and sub-optimal 
cosmesis (OR 8.15, 95% CI 6.08-10.92; p<0.001) at five years. 
Conclusions: Improved dose homogeneity with IMRT translates into 
superior overall cosmesis and reduces the risk of skin telengiectasia at 
5 years post RT. These results are practice-changing and should 
encourage other centres still using 2D standard RT to implement 
breast IMRT. In addition, surgical cosmesis should be optimised as this 
also has a significant effect on late breast toxicities. 
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Purpose/Objective: Radiation therapy (RT) significantly ameliorates 
local control in breast cancer (BC) patients treated with breast 
conserving surgery and in high relapse risk radically resected patients. 
Some debate exist about the value of RT in elderly patients. In this 
retrospective analysis on a single institution series of BC patients we 
evaluate local control as regard to age and different prognostic 
factors. 
Materials and Methods: Patients undergoing postoperative RT for 
localized breast cancer treated at our institution between January 
1999 and December 2008 were the object of the study. RT consisted 
of 50 Gy in 5 weeks on the chest wall, in the case of mastectomy, and 
on residual breast in the case of quadrantectomy or lumpectomy, and 
eventually on the axillar and supraclavear nodes. A boost of 10Gy was 
administered to the tumor bed of all the conserving surgery treated 
patients. The clinical data were analyzed with univariate and 
multivariate analysis considering age (<40, 40-64, ≥65), nodal status 
(N + vs N-), tumor classification (T1 vs >T1), grading (G1–2 vs G3), 
oestrogen and progesterone receptors (ER and PgR), and erb-B2 
status. A further classification of patients according to a surrogate 
approximate genetic signature and recognizing the four subtypes of 
BC, namely luminal A (ER + and/or PgR + , and erb-B2–), luminal B 
(ER+ and/or PgR + , and erb-B2 + ), HER-2 (ER-, PgR– and erb-B2 + ), 
and basal(ER–, PgR– and erb-B2–) was adopted. Freedom from loco-
regional relapse (FFLR) was defined as the time from diagnosis to the 
loco-regional relapse (LR). The 8-year LR rate was estimated by the 
Kaplan-Meier method. 
Results: Seven hundred thirty-three patients with a median age of 53 
years (range 27-84) and with a minimum follow up of 12 months 
entered the study. Chemotherapy, hormonal therapy or both, were 
administered at 57, 374, and 249 patients, respectively. The median 
follow up was 84 months (range 12 – 126), with an overall survival of 
96%. The 8-year actuarial rate of LR was 3%. Univariate analysis 
showed a significant relation of LR with age (LR=6.1% for age<40 
years, LR=1.6% for 40≤age<65, LR=6.5% forage ≥65), grading (LR=1.7% 
for G1–2, LR=4.1% for G3), ER status (LR=2.3% forER-, LR=5.4% for ER+) 
and HER2 subtype (LR=2.3% for no-HER2, LR=8.5% for HER2). From the 
multivariate analysis, age (hazard risk 3.9 for age≥65 years and 3.2for 
age<40 years compared with 40≤age<65) and HER2 subtype (hazard 
risk3.8) were the only significant factors for LR risk prediction (Fig.1). 
 
Figure 1 
 
  
Conclusions: Age less than 40 and equal to or more than 65 years and 
HER-2 subtype are associated with a greater risk of local relapse. 
These results do not support a different RT management of elderly 
patients.  
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Background: Although radiotherapy is a very cost-effective treatment 
modality, it requires major investments for building and equipment. 
Adequate planning of radiotherapy infrastructure and personnel may 
prevent waiting lists and overcapacity with vacancies. In the 
Netherlands, until recently, radiotherapy capacity was regulated by 
the government. Until 2000 this was done by a limitation of the 
number of linear accelerators and since then by a limitation of the 
number of centers. Models have been used to estimate the expected 
number of cancer patients, patients requiring radiotherapy and the 
distribution over different types of treatment (simple, standard, 
intensive, or special). This was used to determine the required 
number of machines and staffing. The actual situation in the 
Netherlands is evaluated annually by a survey of all Dutch centers. 
Materials and methods: For the period from 1998 to 2010, the 
predictions from the Dutch Society of Radiotherapy and Oncology 
were compared with the actual measures from annual surveys of the 
21 Dutch centers. In addition, developments of productivity and 
departments size are evaluated. 
Results: An annual increase in the number of patients and 
radiotherapy treatments of 3.5-4.0 % was observed. The number of 
machines and staffing increased accordingly. After a relative increase 
in the percentage of 3D conformal treatments in the late 1990s and 
early 2000s, a shift from 3D-conformal techniques to intensity 
modulated, image-guided and stereotactic techniques was seen in the 
later years. In 2010, 39% of the treatment series was delivered using 
IMRT, IGRT, SBRT or radiosurgery techniques, 21% using 3D-conformal 
techniques an 40% using standard techniques. In 1998, their were 274 
treatment series per radiation oncologist, 625 per physicist and 532 
per linear accelerator, compared to 249 series per radiation 
oncologist, 540 per physicist and 451 per accelerator in 2010.  
The number of radiotherapy departments did not increase over the 
study period. The average size of the centers was 5.7 accelerators, 
10.4 fte radiation oncologists, 4.8 fte clinical physicists and 45.8 fte 
technologists, compared to 3.2 accelerators and 6.2 fte, 2.7 fte and 
30.4 fte, respectively in 1998.  
Discussion: Prognoses of the number and types of radiotherapy 
treatments allow for an accurate prediction and planning of the 
required staffing and infrastructure to avoid waiting lists and 
overcapacity. The expansion of the existing departments instead of 
the addition of new centers, allows for a more rapid implementation 
of new techniques and will allow sufficient sub-specialization of the 
staff. In recent years, the expansion of departments is often realized 
by establishing ‘satellite centers’, which are an integral part of the 
main center. Treatment planning is performed at the main site and 
the staff rotates over the satellite(s) and the main center. 
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Historically, England has faced an under-provision of radiotherapy, 
due in part to the decentralised nature of equipment procurement 
and workforce management. The ESTRO QUARTS report showed that 
England operated just over 50% of the estimated number of 
megavoltage radiotherapy units estimated as necessary for treatment 
of cancer in the population. 
In 2007 the National Radiotherapy Advisory Group’s report was 
commissioned by Prof. Mike Richards, National Cancer Director. It 
suggested that a 63% increase was required to bridge the gap between 
actual radiotherapy activity (30,000 fractions per million/year) and 
optimum treatment levels(48,000 fractions per million/year). 
Projections of treatment activity suggested that by 2016, activity 
levels of 54,000 fractions per million/year would be required. The 
report recommended a long term strategy for the development and 
expansion of a multi-professional workforce for radiotherapy delivery, 
the expansion and modernisation of radiotherapy delivery services,the 
central collection of radiotherapy treatment statistics, and 
improvement in treatment quality starting with IMRT and moving over 
a decade to 4-D adaptive radiotherapy. A National Radiotherapy 
